Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 389 followers
Latest posts
Last updated about 21 hours ago
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
about 2 months ago
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a...
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
about 1 month ago
INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)...
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
about 1 month ago
Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by...
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
28 days ago
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS...
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
14 days ago
First-of-its-kind study shows sustained Zepbound use in older adults with obesity lowers...
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
12 days ago
Mounjaro is the first and only GIP and GLP-1 receptor agonist proven...
La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2
12 days ago
Mounjaro es el primer y único agonista de los receptores GIP y...
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
9 days ago
Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing...
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
9 days ago
At Week 52, Taltz and Zepbound maintained or further improved psoriasis or...
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
8 days ago
INDIANAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)...
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
5 months ago
Adults taking Foundayo lost an average of 27 pounds on the highest...
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
5 months ago
Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise...